Luye Pharmaceutical (02186) issued an announcement that the company's board of directors announced that the company's new drug in the field of central nervous system LY 03009 has been approved by the US Food and Drug Administration for clinical trials. LY 03009 is used to treat Parkinson's disease and restless leg syndrome and was developed in-house by the company based on its long-acting and sustained-release technology platform.
In addition to the United States, the product is also undergoing Phase I clinical trials in Australia and approved for clinical trials in China. Currently, there are an estimated more than 10 million patients worldwide who suffer from Parkinson's disease; Based on the large patient population and treatment needs, the global Parkinson's drug market size is estimated to reach $4.564 billion in 2020 and is expected to increase to $5.934 billion in 2026 at a COMPOUND annual growth rate of 4.68%.
With the global aging trend, the Board believes that LY 03009 has a good market outlook in the future and will enrich the company's future product portfolio. At the same time, the company has listed a number of products in the field of central nervous system therapy, including risperidone microspheres (II) for injection (reshinto ®), quetiapine fumarate tablets (Sricon ®) and quitisapine fumarate extended-release tablets, Leiss' clear skin patches and Leith's Mingdo day transdermal patches, fentanyl transdermal patches and buprenorphine transdermal patches, covering more than 80 countries and regions around the world, including china, the United States, Europe and Japan, as well as fast-growing emerging markets. In addition, the company has a number of research projects in China and overseas markets for simultaneous development, covering depression, Parkinson's disease and other diseases, forming a rich product portfolio in the field of central nervous system treatment.
![The State Council approved the establishment of cross-border e-commerce comprehensive pilot zones in 27 cities and regions[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)